Regulation, risk and safety of Faecal Microbiota Transplant

Area of Science:

• Gastroenterology and Hepatology
• Microbiology
• Regulatory Science

Background:

• Faecal microbiota transplantation (FMT) has evolved from an experimental approach to a recognized therapy for recurrent Clostridioides difficile infection (rCDI).
• FMT is being explored for other conditions like hepatic encephalopathy and eradicating antimicrobial-resistant organisms, indicating potential for broader applications.
• The lack of a universal definition and incomplete understanding of FMT's mechanism contribute to varied regulatory approaches globally.

Purpose of the Study:

• To review the current status of Faecal microbiota transplantation (FMT) as a therapeutic strategy.
• To discuss the regulatory landscape and its impact on FMT accessibility and research.
• To highlight the safety profile, known risks, and the importance of informed consent for patients undergoing FMT.

Main Methods:

• Literature review of FMT applications, mechanisms, and regulatory frameworks.
• Analysis of safety data, including short-term and long-term risks associated with FMT.
• Examination of regulatory differences across regions (UK, North America, Europe).

Main Results:

• FMT is established for rCDI and shows promise for other indications.
• Regulatory approaches vary significantly, impacting standardization, access, and research.
• FMT is generally safe with proper donor screening; risks are mainly procedural, with long-term effects still under surveillance.

Conclusions:

• FMT is a valuable therapeutic option, particularly for rCDI, with expanding potential.
• Harmonizing regulations and standardizing practices are crucial for wider adoption and research.
• Informed consent is paramount, ensuring patients understand the benefits and risks of FMT.